| |
HCV at IDSA & ICAAC - 23 Reports
|
| |
| |
ICAAC: SVR Tied to Lower Progression, Mortality in HIV/HCV+ With Moderate Fibrosis - the importance of treating coinfected patients -
(MACS Study) Incident Hepatitis C Virus Infection in Men Who Have Sex With Men: A Prospective Cohort Analysis, 1984-2011 'HIV-infection (6-fold), unprotected receptive anal intercourse (3-fold) increase risk for HCV acquisition, low CD4, syphils' - (09/20/13)
IDSA: Barriers to Hepatitis C Treatment in an HIV-HCV Co- Infected Cohort - (10/07/13)
IDSA: High Referral of HCV Patients to Specialists But Low Treatment Initiation Rate - Barriers to Care & Treatment - (10/07/13)
IDSA: Causes of Death among People with Hepatitis C in NYC, 2000-2011 (HCV+ Die 15-26 Yrs Prematurely)- (10/10/13)
IDSA: HIV/Hepatitis C (HCV) Co-infection among Men who have Sex with Men (MSM) in New York City (NYC), 2000-2010 - Increased from 7% to 24% - (10/10/13)
IDSA: Hospitalization among Persons with Chronic Hepatitis C Virus Infection in the United States: The Chronic Hepatitis Cohort Study (CHeCS), 2006-2010 (37% of HCV+ hospitalized; African-Americans have double the rate vs whites)- (10/11/13)
IDSA: Mortality among Persons in Care with Hepatitis C Virus Infection-Chronic Hepatitis Cohort Study (CHeCS), 2006 -2010: HCV deaths grossly Underreported mortality rate 12 times higher than the general population, average age of death is 59 for HCV & 74 for general population, a 15 year difference - (10/11/13)
IDSA: Lack of HCV Genetic Diversity Tied to Higher Liver Disease Risk in Women With HIV - (10/07/13)
HCV NEW DRUGS---------
IDSA: Sofosbuvir and Peginterferon Alfa-2a/Ribavirin for Treatment-Na•ve Genotype 1-4 HCV-Infected Patients Who Are Coinfected With HIV - (10/07/13)
IDSA: Optimization of an Interferon-free Hepatitis C Virus Therapy Regimen Containing the HCV NS3/4A Protease Inhibitor Faldaprevir, the Non-nucleoside NS5B Inhibitor Deleobuvir, and Ribavirin for Genotype-1b-infected Patients - (10/07/13)
Investigational interferon-free regimen demonstrates undetectable hepatitis C virus in all patients reaching end of treatment in ongoing Phase II trial: BI/Presidio Faldaprevir + PPI-668 + Deleobuvir - (10/10/13)
IDSA: Sustained Virologic Response With Daclatasvir Plus Sofosbuvir ± Ribavirin (RBV) in Chronic HCV Genotype (GT) 1-Infected Patients Who Previously Failed Telaprevir (TVR) or Boceprevir (BOC) - (10/10/13)
IDSA: Interim Analysis of an Interferon (IFN)- and Ribavirin (RBV)-Free Regimen of Daclatasvir (DCV), Asunaprevir (ASV), and BMS-791325 in Treatment-Naive, Hepatitis C Virus Genotype 1-Infected Patients - (10/10/13)
IDSA: DACLATASVIR COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN FOR 12 OR 16 WEEKS IN PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 2 OR 3 INFECTION: COMMAND GT 2/3 STUDY - (10/10/13)
EASL: New HCV Drugs - EASL & Beyond
IDSA: Telaprevir-based triple therapy for elderly patients with genotype 1 chronic hepatitis C - (10/07/13)
HCV at ICAAC:
HCV at ICAAC: Tumor Characteristics and Survival in HIV-Infected Patients with Hepatocellular Carcinoma: the Impact of Surveillance - (10/02/13) HCV/HIV connected Mortality very high with no significant changes recently, HIV/HCV+ diagnosed late at advanced stage of disease, they do not receive proper cancer screening surveillance
ICAAC: SVR Tied to Lower Progression, Mortality in HIV/HCV+ With Moderate Fibrosis - the importance of treating coinfected patients -
SVR reduced risk for AIDS progression and serious liver-related events in non-advanced as well as in patients with advanced HCV disease
ICAAC: Lack of Clinically Relevant Drug Interactions Between Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Telaprevir - (09/12/13)
ICAAC: Hepatitis C Eradication Reduces Liver Decompensation, HIV progression, and Death in HIV/HCV-coinfected Patients with non-Advanced Liver Fibrosis - (09/12/13)
ICAAC: Acute C hepatitis in Japanese HIV-infected patients in this decade - (09/31/13)
ICAAC: CLINICAL CHARACTERIZATION OF HIV/HCV CO-INFECTED PATIENTS TREATED WITH DIRECT ACTING ANTIVIRAL AGENTS (in Miami) - (09/18/13)
ICAAC: Worse Response to PegIFN/RBV for HCV After Transplant in HIV/HCV+ vs HCV+
ICAAC: HIV Does Not Affect Chance of HCV Genotype 2 or 3 Responding to PegIFN/RBV
|
|
| |
| |
|
|
|
